WILMINGTON, Mass., May 19, 2015 /PRNewswire/ -- CutisPharma, a specialty pharmaceutical company that develops and distributes bulk drugs in kits used by pharmacists to create compounded medications, today named President Neal Muni, MD, MSPH to the role of Chief Executive Officer.
Neal Muni replaces Indu Muni, Ph.D., who founded CutisPharma in 1998. Indu Muni will remain Chairman of the Board.
"I am excited to build on CutisPharma's impressive growth trajectory and to lead the company as it pursues its long-term strategic vision of transforming compounding through innovation," said Neal Muni. "There are significant needs for high quality and solid science in pharmaceutical compounding, and our company's mission over its 17 years of operation has been to provide patients with better solutions based first and foremost on quality. As recent events demonstrate all too well, the consequences of poor quality in compounded products can be tragic. Our goal from day one has been to follow the best science and manufacturing standards to help pharmacists provide high quality and safe compounded products. Further, we have aimed to do this in a manner that is cost-effective and facilitates better control of compounding utilization by our managed care partners."
Neal Muni has served as the Company's President since July 2014 and since that time has successfully led the development and execution of a number of operational and commercial projects designed to help CutisPharma better serve its customers.
"I am proud of the accomplishments we have made during my 17 years leading CutisPharma," said founder and Chairman Indu Muni. "From our humble beginnings in 1998, starting with just a concept and vision, the company has grown into the well-established industry leader. I believe that Neal Muni's background and expertise make him the right person to lead CutisPharma through the next phase of its growth plan." Indu Muni added.
Among the bulk drug products made by CutisPharma is an omeprazole compounding kit that enables retail pharmacists to create a liquid suspension of this proton pump inhibitor, often used by children and infants, and a vancomycin compounding kit that enables easy preparation of a liquid form of this anti-microbial therapy. The company is also currently preparing an NDA filing for its lead pipeline drug, RM-01 and continues to move aggressively forward with development of additional drugs in its pipeline.
Neal Muni previously served as the Executive Director of New Product Planning at Sunovion Pharmaceuticals, where he led the Corporate Strategy group's commercial assessment of the company's research and development portfolio and corporate mergers and acquisitions and licensing activities. He currently maintains staff appointments with the Department of Medicine at Brigham and Women's Hospital, where he practices as an internist. He is also an Instructor of Medicine at Harvard Medical School. Prior to joining Sunovion, Neal Muni worked in the strategic advisory practice of Leerink Swann and served as a Medical Officer at the U.S. Food and Drug Administration. Neal Muni completed his residency training in internal medicine at the Brigham and Women's Hospital. He received his M.D. as well as Master of Science in Public Health, from the Tulane School of Medicine, and a B.A. in Business Economics and B.Sc. in Biochemistry from Brown University.
CutisPharma, Inc., based in Wilmington, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary pharmaceutical products and technologies in the prescription compounding sector of the health care industry. The product line and development efforts are focused on providing bulk drug products that present optimized, more efficient alternatives for the preparation of compounded prescriptions, by offering FIRST® Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits benefits all key stakeholders, including physicians, pharmacists, and patients.
SOURCE CutisPharma, Inc.